Investors will continue to monitor its ongoing pharmaceutical trials to determine if the stock will be able to reverse its downturn. OwensAssetFund.com now owns 99 shares
Wow. A "going concern" letter.
I suppose the only reason this is not zero is the hope of future cash flow coming through.
I think the U.S. market has rejected this company. IMO, they will probably delist here and then just trade in China. The government over there will loan them money to keep them alive. They will essentially be owned by the government.
How is stock not delisted? Has it received a delist notice yet?
From last year's annual report. Sales will not show up on this next annual report, but moving forward, sales should be substantial.
On June 8, 2015, the China Food and Drug Administration ("CFDA") issued to Aoxing Pharma's subsidiary licenses to produce Tilidine Hydrochloride tablets (“Tilidine HCL”). Registration Certificate 2015S00391 was issued for the 50mg tablet; Registration Certificate 2015S00390 was issued for the 100mg tablet. This approval is the culmination of multiple years of research, development and regulatory activities. Our entry into the market will be a significant break-through in China's fight to treat pain. Tilidine HCL tablets offer a convenient medium for delivery of this drug, which is essential in the fight against pain. We will be the sole producer of Tilidine HCL tablets in China.
Tilidine hydrochloride is an orally-absorbed synthetic narcotic analgesic. It is used in 50mg or 100mg dosage strength for relief of acute, moderate to severe pain, and chronic cancer-related pain. Tilidine hydrochloride is currently selling in European countries, including Germany, Belgium, Ireland, Italy and Switzerland and is not available in China at the moment.
It is estimated that there are at least 50 million operation procedures performed in Chinese hospitals and clinical centers every year, and 50% of these procedures require acute post-operative pain treatment. In addition, there are estimated to be over 2.2 million newly diagnosed cancer patients every year, and 60% of them are unable to receive necessary pain management under the current treatment paradigm.
HOW DO YOU GET TO THE MARKET PULSE AND MESSAGE BOARD